Medical Devices & Digital Health - Obesity/Weight Loss Treatment
Strategic Profile
The Smart Capsule is a non-surgical, 15-minute orally administered device that resides approximately 4 months in the stomach and targets adults with BMI 30-40, opening access to approximately 80 million Americans with obesity. The company is pursuing strategic partnerships for expansion in Latin American markets, including a partnership with Bionut in Argentina that integrates cutting-edge weight loss methods like the Smart Capsule.
Cyborg Score Rationale
Allurion received notice from the NYSE that it intends to initiate delisting proceedings after failing to maintain either $50 million in stockholders' equity or $50 million in total market capitalization on a 30-trading day average basis. Despite a gross margin of 61%, the company suffered with a negative -199.95% total profit margin and negative EBIT margins, highlighting ongoing struggles in maintaining expense control.
Top Insights
FDA approved Allurion Smart Capsule on February 23, 2026, a major regulatory milestone enabling market access to ~80 million Americans with obesity (BMI 30-40)
Clinical case series combining Smart Capsule with low-dose tirzepatide (2.5-5.0 mg) showed 23% average total body weight loss at 12 months and 14-point increase in lean body mass share
Company facing NYSE delisting proceedings but has right to appeal; expects continued trading during appeal process while working to regain compliance
Recent financials show revenue of $32.11M but negative profitability with enterprise value of $40.64M and severe operating losses
Named Competitors
Mounjaro/Tirzepatide — GLP-1 weight loss medication; used in combination with Allurion Smart Capsule
Traditional Bariatric Surgery — Surgical weight loss alternative; invasive but with established long-term data
Ozempic/Wegovy — GLP-1 agonist for weight loss; medication-only approach without device
Recent Developments
(March 2026) NYSE initiates delisting proceedings; company appeals and seeks to regain compliance through capital raising and debt restructuring
(February 2026) FDA grants premarket approval for Allurion Smart Capsule; Chardan Capital upgrades to Buy
(February 2026) Partnership with Bionut and Farmastar in Argentina to offer discounted Mounjaro (tirzepatide) with Smart Capsule
(Q4 2025) New commercial strategy implemented after strategic pivot contributes to revenue growth
Open the full interactive Allurion Technologies, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.